This report presents details of a clinical trial of tetrahydrozoline hydrochloride (Tyzine), a new sympathomimetic agent useful in 0.1% aqueous solution as a topical vasoconstrictor and nasal decongestant.
The effectiveness of tetrahydrozoline, as measured by its promptness of action, degree of relief provided, and the percentage of patients benefited, is superior.
The decongestive action of tetrahydrozoline is notably prolonged, so that instillations every four to eight hours, or at longer intervals in some cases, are sufficient to maintain continuous relief; instillation at bedtime provides relief that carries through the night.
Tetrahydrozoline is also free of both local and systemic side-effects.
Pharmacologic tests with tetrahydrozoline, which is designated chemically as 2-(1,2,3, 4-tetrahydro-1-naphthyl) imidazoline hydrochloride, suggested that this recently synthesized compound should prove highly effective and free of the disadvantages of its predecessors. The structural formula of tetrahydrozoline is as follows:Tetrahydrozoline consists structurally of an aromatic nucleus and a side radical
NEISTADT I. Clinical Trial of Tetrahydrozoline Hydrochloride: A Valuable New Nasal Decongestant. AMA Arch Otolaryngol. 1955;62(2):143–144. doi:10.1001/archotol.1955.03830020025005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: